Surface Oncology Inc (SURF) Quote

get ready to rumble...as the trend gets ready to test 1.15!

SURF ready to surf the wave

SURFING THE SURF WAVE IS THE PLAY OF TNHE DAY!!

surf is up....ride the wave!!!!!

Does this take off soon?

So quiet???

Why do quiet here?

SURF...$4.43...Bullish Harami Cross Reversal pattern to the Upside...

Chart... https://schrts.co/SGTGjDrM ...

SURF...$5.02s clearing here on the Piercing Line Reversal Pattern to the Upside on this Oversold Chart ...imo...we shall see...:partying_face: ... https://schrts.co/ANfpjBuF ...

SURF...$5.80...in the P/M...Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study ...:party:

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for GSK4381562 (formerly SRF813) to proceed into a first-in-human clinical trial. GSK4381562 is a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells.

In December 2020, Surface announced it had entered into an agreement in which GSK exclusively licensed worldwide development and commercial rights to GSK4381562. Surface will receive a $30 million milestone payment in conjunction with the initiation of the first Phase 1 study for GSK4381562 and is eligible to receive an additional $700 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales...
[7:43 AM]
georgie18 — 11/04/2021
SURF...$7.73...Long Term Cup N Handle Continuation Pattern...with 45 Million range O/S...Target...$27...Break/Hold $18 range and you hit Blue Skies with NO Topside resistance...imo...we shall see... https://schrts.co/rGqEChPJ ...Long Hold for me...:party:

SURF...$7.45...in the P/M...https://finance.yahoo.com/news/preclinical-data-supporting-therapeutic-potential-131000998.html

SURF...$7.73...Long Term Cup N Handle Continuation Pattern...with 45 Million range O/S...Target...$27...

Break/Hold $18 range and you hit Blue Skies with NO Topside resistance...imo...we shall see...

Long Hold for me...:partying_face:

Chart... https://schrts.co/rGqEChPJ ...

SURF...$8.17s clearing here...:party:
[9:59 AM]
georgie18 — 08/04/2021
SURF...$5.18...Oversold Pincher Squeezing here...Reversal setting up...imo...we shall see...:party:

SURF...$7.81...off the $5 range alert...:partying_face:
[10:50 AM]
georgie18 — 08/04/2021
SURF...$5.18...Oversold Pincher Squeezing here...Reversal setting up...imo...we shall see...:partying_face:

SURF...$5.18...Oversold Pincher Squeezing here...Reversal setting up...imo...we shall see...:partying_face:

SURF...$7.90...Looking for a 50ma Bouncer and a Break/Hold of the Strong $9 range Resistance area...imo...we shall see...

Doubling down in this range...

Chart...https://schrts.co/RJXAbqpX ...

SURF...$9.50...in the P/M...https://finance.yahoo.com/news/surface-oncology-collaborate-roche-immuno-110000277.html

Chart from my $5.95 alert...https://schrts.co/FjWXtanS ...

Selected Anticipated Near-term Corporate Milestones:

SRF388 clinical data presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, to be held virtually June 4-8, 2021.
Webcast to provide data from ongoing SRF388 and SRF617 Phase 1 clinical studies, to be held on Friday, June 4, 2021 at 8:00 a.m. ET.
Investigational new drug (IND) filing for SRF813, partnered with GlaxoSmithKline, anticipated in 2021.

SURF...$8.79...Gapping Here...:party:

SURF...$8.24...looking for the 200ma breakout...imo...we shall see...:party:
georgie18 — 05/05/2021
SURF...$7.41...Psar flipped to a Bullish Buy Position on the Bullish Engulfing Candle...:party:

SURF...$7.25...Bullish Engulfing Reversal candle to the Upside...Psar flipped to a Bullish Buy Position...

Added more @6.95
GLTA!

Surfing around daily MA200, made an entrance here.
GLTA!

Surface Oncology Granted Application By U.S. Patent Office For Patent Titled 'The invention provides anti-CD39 antibody compositions and their use in treating cancer.'

Link

I was holding otm calls before the news. Yummy.

Good Luck!

SURF...$7.97...in the A/H...CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for one of the company’s lead therapeutic candidates, SRF617, for the treatment of patients with pancreatic cancer.
“We are pleased to receive this important designation from the FDA, which supports our conviction that new immunotherapies for pancreatic cancer are urgently needed,” said Alison O’Neill, M.D., senior vice president, clinical development at Surface Oncology. “We are very encouraged by our clinical progress to date with SRF617, a highly innovative therapy with the potential to promote anti-tumor immunity in patients with cancer. SRF617 is in Phase 1/1b studies across a variety of solid tumors, including combination studies with gemcitabine and abraxane in patients with pancreatic cancer.”...:party:

SURF After Hours FDA News , " Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer "
News Out After Hours Tuesday
Up 19% AH on Very Heavy Volume.

https://finance.yahoo.com/news/surface-oncology-srf617-receives-orphan-203000832.html

Motley Fool Thur Evening..
https://www.fool.com/investing/2021/03/30/why-surface-oncology-is-flying-higher-after-hours/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

TradingView - Buy Rated Tech. Analysis
https://www.tradingview.com/symbols/NASDAQ-SURF/technicals/

Finviz
https://elite.finviz.com/quote.ashx?t=surf

68% Increase in message volume and Large Rise in sentiment,,,
https://stocktwits.com/symbol/SURF

Maybe Be A Very HOT Stock Premarket, before Reg Hours Volume smacks it even higher..

May The Force Be with You ......
May The Energy Be Yours.....

$SURF @FDA_Drug_Info Low float. Looking great for a possible huge runner tomorrow. Next $EYES ?? https://finance.yahoo.com/news/surface-oncology-srf617-receives-orphan-203000832.html

SURF wiping out its big losses today in AH on..

Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

G.M._Fress_& Board Thank you, I gave you a Follow. I'll pick up some
shares of -"SURF"-
Thanks again & have a good one

Copy that not sure if she is I know they still hold a boat load of shares.


$SURF

SURF swimming against the Daq current and succeeding (for now). Interesting. Cathy still buying?

Fress. Surf Is my Favorite Bio. But Entertainment Wise "Video Streaming Platforms" Are The Future. Their Target Advertising Alone Is Very Lucrative. CHINA=ABQQ otc fully Reporting @ INDIA=CIDM Nasdaq

SURF...$8.00 in the P/M...CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF388, an investigational antibody therapy targeting IL-27, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1 study of SRF388 and will be evaluated in patients with solid tumors, with a focus on patients with liver cancer and kidney cancer.

“Surface is the only company with clinical-stage IL-27 research and we believe that this cytokine may play an important role in resistance to anti-PD-1 treatment,” said Rob Ross, M.D., incoming chief executive officer at Surface Oncology. “This collaboration with Merck will add an important dimension to the SRF388 clinical program and allow us to more rapidly assess its potential to deliver truly breakthrough therapies that can transform treatment for people with cancer.”

waiting to see if there is a complete melt down across the board on the nasdaq. Thinking Nasdaq under 10k is in the cards.


$SURF

You adding this dip?

SURF they have 6 very promising antibody molecules.

GSK puts up to $815M on the table for Surface Oncology's antibody.
https://www.fiercebiotech.com/biotech/gsk-puts-up-to-815m-table-for-surface-oncology-s-antibody

Surface Oncology (SURF) Explores Potential Sale After GSK Takeover Approach - Source
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html

Cathie Wood from ARKG has been buying SURF everyday a million share purchase in one day a few weeks back.

2021/2/16
ARKG 3,883,960 (+35,028)
9.55% of outstanding shares.

Novartis 9.71% holding.

Eli Lily holds 8.5% through LLV ventures fund.

Cash runway into 2023

Licensing agreements with $NVS $GSK and $MRK??


SRF617 (100% OWNED) - Targets CD39
SRF388 (100% OWNED) - Targets IL27
SRF813 (GSK 830M DEAL) - Targets PVRIG
NZV930 (Deal with Novartis)
SRF114 Targets CCR8

Cup and handle forming on the weekly!
Take a look at this chart get in before the pop to $15-$20
https://stockcharts.com/h-sc/ui?s=surf


$SURF

2021/2/16
ARKG 3,883,960 (+35,028)
9.55% of outstanding shares


$SURF

There is a RAF Fire trigger on the 30 min this is very close to bottoming out and on its way to new 52 week highs.

Cup and Handle forming on the weekly.


Catch a wave.



$SURF

Cathie Wood from ARKG owns 10% and keeps adding shares. of the SURF float.

Eli Lily holds 8.5% through LLV ventures fund.

Novartis owns 10% institutions own 67% of the 40 million shares outstanding.

institutions own 68% of the 40 million shares outstanding.

Potential of 1.2 Billion in total payments from Novartis & GSK with double digit royalties. Also partnered with Merck.

https://www.fiercebiotech.com/biotech/gsk-puts-up-to-815m-table-for-surface-oncology-s-antibody

Surface Oncology (SURF) Explores Potential Sale After GSK Takeover Approach - Source
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html

Jim Cramer Surface Oncology Is Set for Further Gains.
https://realmoney.thestreet.com/investing/surface-oncology-is-set-for-further-gains-how-to-buy-it-15542979

http://www.surfaceoncology.com


Golden Chart!
https://stockcharts.com/

$SURF

Rgls has a lot of the same ownership...minus aunt kathy...interesting

SEC Form SC 13G/A filed
https://quantisnow.com/insight/399449?s=s

Follow the bread crumbs!


Added to my stash!!

Surface Oncology (SURF) Explores Potential Sale After GSK Takeover Approach - Source
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html

Charts Golden
https://stockcharts.com/h-sc/ui?s=SURF

Cathie Wood of ARKG keeps buying SURF wonder why? million share buy a few weeks back.And she keeps increasing her SURF position day after day!


$SURF

Cathie Wood from ARKG literally bought a cool million SURF shares in one day a few weeks ago. She has the best financial research team & tools and is in close contact with SURF management. ARKG Cathie Wood now owns close to 10% of the shares and she has been Buying SURF shares almost every day.

Surface Oncology hires bankers to explore sale - StreetInsider


The company received a takeover approach from GlaxoSmithKline (GSK)
and has hired an investment bank, StreetInsider reports.
Surface Oncology wants bankers to look for any other possible M&A interest beyond GSK, StreetInsider says.
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html

FDA Fast tracks SRF388 (Surface Oncology), a fully human anti-interleukin-27 antibody, for treatment of patients with hepatocellular carcinoma

Cathie Wood from ARKG owns 10% and keeps adding shares. of the SURF float Eli Lily holds 8.5% through LLV ventures fund. Novartis just disclosed a roughly 10% stake after hours via Form SC 13G. institutions own 67% of the 40 million shares outstanding

Cash runway through 2023 ($102.5M in cash as of Sept 30th; received $85Million from GSK GlaxoSmithKline in December.


Two strategic partnerships (Novartis & GSK GlaxoSmithKline) validate strong IO drug discovery capabilities.

GSK GlaxoSmithKline Partnership SRF813
cumulative milestones up to $730 million
• Tiered royalties on annual net sales
(high single-digit to mid-teens %

Novartis Partnership: NZV930

• Upfront payment of $70M, total
cumulative milestones up to $525 million
• Tiered royalties on annual net sales
(high single-digit to mid-teens %)


Detailed clinical update for both SRF617 & SRF388 to be presented in the first half of 2021.

SRF388 is the ONLY anti IL-27 targeted agent in clinical development. Shows antimetastatic tumour activity and increased the production of key inflammatory cytokines.

SRF388 is a blockbuster in the making, the Il-27 targeting antibody. There is compelling evidence clinically to understand IL-27s role in tumour types. This is the next one that will get huge partnership deal!!



Total = $1.2B Billion just for licence worldwide rights with Novartis & GSK plus double digit tiered royalties.

Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer.
https://investors.surfaceoncology.com/news-releases/news-release-details/surface-oncology-announces-fda-fast-track-designation-granted-us

SURF has 4 other VERY promising targets. SRF617,SRF388, SRF114,SRF231 More partnership deals to come.
undervalued and the chart is bullish 1 year is amazing building & looking for continuation to the upside.

SURF Chart cup and handle on the weekly!!
https://stockcharts.com/h-sc/ui?s=SURF

Outstanding team of experienced company builders & oncology drug developers.



In the "Lightning Round" segment of Mad Money Friday night, Jim Cramer was bullish on Surface Oncology (SURF) , an immuno-onocolgy company developing next-generation antibody therapies.
https://realmoney.thestreet.com/investing/surface-oncology-is-set-for-further-gains-how-to-buy-it-15542979



SURF Feb 2021 Biz presentation:
https://investors.surfaceoncology.com/static-files/9a6d888d-dae2-419d-a0fc-c96058f9aa7c

Surf Website:
https://www.surfaceoncology.com/

Surf Pipeline & Programs:
https://www.surfaceoncology.com/pipeline-programs/

$SURF

thanks fress im in

Huge cup and handle forming on the weekly.


Continue uptrend. New highs in the forecast.


MACD turning up here along with RSI would be very bullish.


https://stockcharts.com/h-sc/ui?s=SURF


Cathie Wood from ARKG has been buying SURF aggressively and doubled her position in 2021 4 million shares. She liked TSLA at $30.00 Bitcoin at $500 Cathie Knows.

Novartis owns 10% of the total shares.
Eli Lily holds 8.5% through LLV ventures fund.
institutions own 67% of the 40 million shares outstanding



$SURF

It's a bull chart;





https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161838832

God Bless

SURF Daily chart

Catalysts for 1st half of 2021: Filing of IND (investigational new drug) status for SRF813. Results for SRF617 and results for 388.

Surface Oncology hires bankers to explore sale - StreetInsider

Surface Oncology (SURF, +16%) is climbing sharply on a report that its exploring a sale.

The company received a takeover approach from GlaxoSmithKline (GSK)
and has hired an investment bank, StreetInsider reports.
Surface Oncology wants bankers to look for any other possible M&A interest beyond GSK, StreetInsider says.
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html

In the "Lightning Round" segment of Mad Money Friday night, Jim Cramer was bullish on Surface Oncology (SURF) , an immuno-onocolgy company developing next-generation antibody therapies.
https://realmoney.thestreet.com/investing/surface-oncology-is-set-for-further-gains-how-to-buy-it-15542979


Cathie Wood ARKG #1 wall street stock picker bought over a million SURF shares in one day a few weeks back she has doubled her position to over 4 million shares in the stock recently Cathie knows something!

Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer.
https://investors.surfaceoncology.com/news-releases/news-release-details/surface-oncology-announces-fda-fast-track-designation-granted-us

SURF chart.
https://stockcharts.com/h-sc/ui?s=surf


Surface Oncology is a clinical-stage immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment.


SURF Partnership's with Novartis worth
$525M
(For SRF373)Partnership with GSK GlaxoSmithKline worth
$730M
(For SRF813)
Total = 1.15B just for licence worldwide rights.



Feb 2021 Biz presentation:
https://investors.surfaceoncology.com/static-files/9a6d888d-dae2-419d-a0fc-c96058f9aa7c

Surf Website:
https://www.surfaceoncology.com/

Surf Pipeline & Programs:
https://www.surfaceoncology.com/pipeline-programs/




$SURF

Excellent DD Fress...thank you!

Cathie Wood from ARKG owns 10% and keeps adding shares. of the SURF float Eli Lily holds 8.5% through LLV ventures fund. institutions own 67% of the 40 million shares outstanding

Cash runway through 2023 ($102.5M in cash as of Sept 30th; received $85Million from GSK GlaxoSmithKline in December.


Two strategic partnerships (Novartis & GSK GlaxoSmithKline) validate strong IO drug discovery capabilities.

GSK GlaxoSmithKline Partnership SRF813
cumulative milestones up to $730 million
• Tiered royalties on annual net sales
(high single-digit to mid-teens %

Novartis Partnership: NZV930

• Upfront payment of $70M, total
cumulative milestones up to $525 million
• Tiered royalties on annual net sales
(high single-digit to mid-teens %)


Detailed clinical update for both SRF617 & SRF388 to be presented in the first half of 2021.

SRF388 is the ONLY anti IL-27 targeted agent in late Pre clinical development. Shows antimetastatic tumour activity and increased the production of key inflammatory cytokines.

SRF388 is a blockbuster in the making, the Il-27 targeting antibody. There is compelling evidence clinically to understand IL-27s role in tumour types. This is the next one that will get huge partnership deal!! Can’t wait for phase 1 data.


Surf recap: Partnership with Novartis worth
$525M
(For SRF373)Partnership with GSK GlaxoSmithKline worth
$730M
(For SRF813)
Total = 1.15B just for licence worldwide rights.

SURF has 4 other VERY promising targets. SRF617,SRF388, SRF114,SRF231 More partnership deals to come.
undervalued and the chart is bullish 1 year is amazing building & looking for continuation to the upside.

https://stockcharts.com/h-sc/ui?s=SURF

Outstanding team of experienced company builders & oncology drug developers.



Feb 2021 Biz presentation:
https://investors.surfaceoncology.com/static-files/9a6d888d-dae2-419d-a0fc-c96058f9aa7c

Surf Website:
https://www.surfaceoncology.com/

Surf Pipeline & Programs:
https://www.surfaceoncology.com/pipeline-programs/

$SURF